增加CSN5表达增加了多发性骨髓瘤细胞对利那利多米德的敏感性
Takumi Yamamoto1, Arisu Furukawa1, Yue Zhou2
1Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
iScience
|December 17, 2024
概括
这项研究表明,较低的CSN5蛋白水平通过影响蛋白质降解途径,有助于在多发性骨髓瘤 (MM) 中对利那利多米德 (LEN) 耐药性. 了解这种机制可能有助于开发针对LEN耐药MM的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 列纳利多米德 (LEN) 是多发性骨髓瘤 (MM) 的关键治疗方法.
- 一些患者发生了对LEN的初级耐药性,其潜在机制尚未完全理解.
- 识别耐药机制对于改善MM治疗至关重要.
研究的目的:
- 确定与MM中原发性莱纳利多米德耐药性相关的蛋白质表达特征.
- 阐明CSN5在莱纳利多米德耐药性中的作用.
- 探索涉及莱纳利多米德耐药性的分子途径.
主要方法:
- 结合lenalidomide敏感性测试与15MM细胞系的蛋白质组学数据.
- 研究了蛋白质降解途径,包括无处化和无处-蛋白酶体系统.
- 分析了CSN5与库林-RING结合酶复合物的相互作用.
主要成果:
- 与敏感细胞相比,在抗莱纳利多米德的MM细胞系中,CSN5的表达显着较低.
- CSN5通过库林-RING泛素酶 (CRL) 介导的泛素-蛋白酶路径通过在lysine 194处的泛素化降解.
- 减少的CSN5表达破坏了CRL4A无化循环,抑制了lenalidomide诱导的IKZF1和IKZF3.3的降解.
结论:
- 较低的CSN5表达代表了多发性骨髓瘤中原发性莱纳利多米德耐药性的新机制.
- 这些发现突出了CSN5-CRL4A-IKZF轴在莱纳利多米德敏感性中的重要性.
- 这项研究可能为开发克服MM患者勒纳利多米德耐药性的策略铺平道路.
相关概念视频
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
01:15Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
02:40Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K